Comparison of the effectiveness of geranylgeranylacetone with cimetidine in gastritis patients with dyspeptic symptoms and gastric lesions: A randomized, double-blind trial in Japan

Digestion

Volumn 75, Issue 4, 2007, Pages 215-224

  Sakamoto, Choitsu ^a   Ogoshi, Kazuei ^b   Saigenji, Katsunori ^c   Narisawa, Rintarou ^d   Nagura, Hiroshi ^e   Mine, Tetsuya ^f   Tada, Masahiro ^g   Umegaki, Eiji ^h   Maekawa, Takama ⁱ   Maekawa, Ryuichiro ^j   Maeda, Kazuhiro ^k  

^a NIPPON MEDICAL SCHOOL   (Japan)

^b NIIGATA CANCER CENTER HOSPITAL   (Japan)

^c KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d NIIGATA UNIVERSITY MEDICAL AND DENTAL HOSPITAL   (Japan)

^e Sendai Shakaihoken Hospital   (Japan)

^f TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g SAITAMA CANCER CENTER   (Japan)

^h OSAKA MEDICAL COLLEGE   (Japan)

ⁱ NATIONAL HOSPITAL ORGANIZATION KYOTO MEDICAL CENTER   (Japan)

^j Social Insurance Tagawa Hospital   (Japan)

^k NATIONAL HOSPITAL ORGANIZATION KUMAMOTO MEDICAL CENTER   (Japan)

more..

Author keywords

Dyspepsia; Gastritis; Geranylgeranylacetone; H2 receptor antagonist; Mucosal erosion; Petechial hemorrhage

Indexed keywords

CIMETIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; TEPRENONE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DYSPEPSIA; FEMALE; GASTRITIS; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; HUMAN TISSUE; JAPAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PETECHIA; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; STOMACH LESION; SYMPTOM;

ANTI-ULCER AGENTS; CIMETIDINE; DITERPENES; DOUBLE-BLIND METHOD; DYSPEPSIA; FEMALE; GASTRITIS; GASTROSCOPY; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; JAPAN; MALE; MIDDLE AGED; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 36748998953     PISSN: 00122823     EISSN: None     Source Type: Journal    
DOI: 10.1159/000110654     Document Type: Article

References (31)

1. Cloud ML, Enas N, Humphries TJ, Bassion S: Rabeprazole in treatment of acid peptic diseases: results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD). The Rabeprazole Study Group. Dig Dis Sci 1998;43:993-1000.
2. 2-receptor antagonists during the use of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2003; 18: 1137-1147.
3. Herrerias-Gutierrez JM, Pardo L, Segu JL: Sucralfate versus ranitidine in the treatment of gastric ulcer. Randomized clinical results in short-term and maintenance therapy. Am J Med 1989;86:94-97.
4. Gonvers JJ, Aenishänslin W, Backwinkel K, Bretholz A, Egger G, Feyerabend H, Fumagalli I, Güller R, Hammer B, Mattle WP, et al: Gastric ulcer: a double blind comparison of 800 mcg misoprostol versus 300 mg ranitidine. Hepatogastroenterology 1987;34:233-235.
5. Warren JR, Marshall BJ: Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1983;1:1273-1275.
6. European Helicobacter Pylori Study Group (EHPSG): Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. Gut 1997;41:8-13.
7. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ: Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007;56:772-781.
8. Berstad AE, Hatlebakk JG, Maartmann-Moe H, Berstad A, Brandtzaeg P: Helicobacter pylori gastritis and epithelial cell proliferation in patients with reflux oesophagitis after treatment with lansoprazole. Gut 1997;41:740-747.
9. Miwa T, Miyoshi A: Famotidine in the treatment of gastritis: Scand J Gastroenterol 1987;134(suppl):46-50.
10. Haruma K, Ito M, Kido S, Manabe N, Kitadai Y, Sumii M, Tanaka S, Yoshihara M, Chayama K: Long-term rebamipide therapy improves Helicobacter pylori-associated chronic gastritis. Dig Dis Sci 2002;47:862-867.
11. Oketani K, Murakami M, Fujisaki H, Wakabayashi T, Hotta K: Effect of geranylgeranylacetone on aspirin-induced changes in gastric glycoproteins. Jpn J Pharmacol 1983;33:593-601.
12. Terano A, Hiraishi H, Ota S, Sugimoto T: Geranylgeranylacetone, a novel anti-ulcer drug, stimulates mucus synthesis and secretion in rat gastric cultured cells. Digestion 1986;33:206-210.
13. Hirakawa T, Rokutan K, Nikawa T, Kishi K: Geranylgeranylacetone induces heat shock proteins in cultured guinea pig gastric mucosal cells and rat gastric mucosa. Gastroenterology 1996;111:345-357.
14. Tanaka K, Tsutsumi S, Arai Y, Hoshino T, Suzuki K, Takaki E, Ito T, Takeuchi K, Nakai A, Mizushima T: Genetic evidence for a protective role of heat shock factor 1 against irritant-induced gastric lesions. Mol Pharmacol 2006;71:985-993.
15. Shirakabe H, Takemoto T, Kobayashi K, Ogoshi K, Kimura K, Nakamura K, Watanabe H: Clinical evaluation of teprenone, a mucosal protective agent, in the treatment of patients with gastric ulcers: a nationwide, multicenter clinical study. Clin Ther 1995;17:924-935.
16. Nagasawa Y, Tatsuta M, Iishi H, Ishiguro S: Prevention of gastric ulcer recurrence with tetraprenylacetone. Scand J Gastroenterol 1998;33:44-48.
17. Qian Y, Si JM, Wu JG, Chen SJ, Zhu YF, Sun KK, Deng YY, Chen K, Wang LJ, Liu WL: Effect of mucosal protective on the quality of gastric ulcer healing. Zhejiang Da Xue Xue Bao Yi Xue Ban 2007;36:71-77.
18. 2-receptor blocker or sucralfate, suppresses corpus Helicobacter pylori colonization and gastritis in humans: teprenone inhibition of H. pylori - induced interleukin-8 in MKN28 gastric epithelial cell lines. Helicobacter 2004;9:130-137.
19. Asaka M, Satoh K, Sugano K, Sugiyama T, Takahashi S, Fukuda Y, Ota H, Murakami K, Kimura K, Shimoyama T: Guidelines in the management of Helicobacter pylori infection in Japan. Helicobacter 2001;6:177-186.
20. Lanza F, Peace K, Gustitus L, Rack MF, Dickson B: A blinded endoscopic comparative study of misoprostol versus sucralfate and placebo in the prevention of aspirin-induced gastric and duodenal ulceration. Am J Gastroenterol 1988;83:143-146.
21. Dixon MF, Genta RM, Yardley JH, Correa P: Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996;20:1161-1181.
22. Logan RP, Walker MM, Misiewicz JJ, Gummett PA, Karim QN, Baron JH: Changes in the intragastric distribution of Helicobacter pylori during treatment with omeprazole. Gut 1995;36:12-16.
23. Eissele R, Brunner G, Simon B, Solcia E, Arnold R: Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia. Gastroenterology 1997;112:707-717.
24. Hassan S, Kinoshita Y, Min D, Nakata H, Kishi K, Matsushima Y, Asahara M, Wang HY, Okada A, Maekawa T, Matsui H, Chiba T: Presence of prostaglandin EP4 receptor gene expression in a rat gastric mucosal cell line. Digestion 1996;57:196-200.
25. Tatsuta M, Yamamoto R, Iishi H, Nakaizumi A: Scanning electron microscopic observations on gastric mucus secretion in rats, and the effects of tetraprenylacetone. Digestion 1995;56:175-180.
26. Ushijima H, Tanaka K, Takeda M, Katsu T, Mima S, Mizushima T: Geranylgeranylacetone protects membranes against nonsteroidal anti-inflammatory drugs. Mol Pharmacol 2005;68:1156-1161.
27. Tomisato W, Takahashi N, Komoto C, Rokutan K, Tsuchiya T, Mizushima T: Geranylgeranylacetone protects cultured guinea pig gastric mucosal cells from indomethacin. Dig Dis Sci 2000;45:1674-1679.
28. Yanagawa A: Prophylactic effect of teprenone against gastroduodenal lesions caused by non-steroidal anti-inflammatory drugs (NSAIDs): controlled trial using the envelope method and placebo-controlled double-blind trial. J Rheumatol 2000;3:191-197.
29. Dekigai H, Nakamura H, Bai J, Tanito M, Masutani H, Hirota K, Matsui H, Murakami M, Yodoi J: Geranylgeranylacetone promotes induction and secretion of thioredoxin in gastric mucosal cells and peripheral blood lymphocytes. Free Radic Res 2001;35:23-30.
30. Gotou Y, Debas HT: Geranylgeranylacetone, a new acyclic polyisoprenoid antiulcer agent - mechanisms of action. Gastroenterology 1984;86:1094.
31. 2-receptor antagonists: interactions between Helicobacter pylori density and pH. Helicobacter 2004;9:17-27.